Status: Recruiting
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Participants needed: 12
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Grit BiotechnologyUpdated: Apr 14, 2026Locations: 1
Eligibility criteria
Voluntarily join the study, signed informed consent form, willing and able to co... [+3]
CNS dysfunction with clinical significance. For example, seizures, cerebral isch... [+3]